Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Positive entities : Novartis ag save search
Novartis Fabhalta® (iptacopan) receives positive CHMP opinion as first oral monotherapy for adult patients with paroxysmal nocturnal hemoglobinuria (PNH)
Published: 2024-03-22 (Crawled : 12:00) - globenewswire.com
NVS | $94.41 0.95% 0.0% 1.4M
|
Health Technology
|
| O: 0.17%
H: 0.28%
C: -0.01%
fabhalta first chmp positive novartis
Novartis delivers strong full year performance, 10% net sales and 18% core operating income growth (cc¹), with margin expansion. Continuing innovation momentum with multiple positive Ph3 readouts
Published: 2024-01-31 (Crawled : 06:00) - globenewswire.com
NVS | $94.41 0.95% 0.0% 1.4M
|
Health Technology
|
| O: -2.04%
H: 0.19%
C: -1.97%
sales year momentum positive innovation novartis growth
Sandoz receives positive CHMP opinion for breast and gastric cancer biosimilar trastuzumab
Published: 2023-09-18 (Crawled : 06:00) - globenewswire.com
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: -0.05%
H: 0.0%
C: -1.31%
NVS | $94.41 0.95% 0.0% 1.4M
|
Health Technology
|
| O: 0.06%
H: 0.09%
C: -0.6%
biosimilar chmp breast positive cancer
Sandoz announces positive results from Mylight Phase lll study for biosimilar aflibercept
Published: 2023-08-15 (Crawled : 06:00) - globenewswire.com
NVS | $94.41 0.95% 0.0% 1.4M
|
Health Technology
|
| O: -0.32%
H: 0.18%
C: -0.44%
biosimilar positive results study
Sandoz receives positive CHMP opinion for multiple sclerosis biosimilar natalizumab
Published: 2023-07-24 (Crawled : 06:00) - globenewswire.com
NVS | $94.41 0.95% 0.0% 1.4M
|
Health Technology
|
| O: -0.05%
H: 0.24%
C: -0.83%
biosimilar chmp positive sclerosis
Novartis Entresto receives positive CHMP opinion for pediatric heart failure
Published: 2023-03-31 (Crawled : 12:00) - globenewswire.com
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: -0.95%
H: 2.14%
C: 2.14%
NVS | $94.41 0.95% 0.0% 1.4M
|
Health Technology
|
| O: 0.22%
H: 0.45%
C: 0.24%
chmp positive novartis heart
Sandoz receives positive CHMP opinion for citrate-free high concentration formulation of adalimumab biosimilar
Published: 2023-01-30 (Crawled : 07:00) - globenewswire.com
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: 0.0%
NVS | $94.41 0.95% 0.0% 1.4M
|
Health Technology
|
| O: 0.65%
H: 0.37%
C: -0.48%
biosimilar chmp positive
Sandoz announces further progress on its biosimilar pipeline, with release of positive results for denosumab integrated Phase I/III clinical trial
Published: 2022-09-19 (Crawled : 06:00) - globenewswire.com
NVS | $94.41 0.95% 0.0% 1.4M
|
Health Technology
|
| O: -0.52%
H: 0.69%
C: 0.62%
AMGN | $265.505 -0.66% -0.67% 1.7M
|
Health Technology
|
| O: -0.22%
H: 0.1%
C: 0.05%
biosimilar trial positive
Novartis receives positive CHMP opinion for Scemblix®, a novel treatment for adult patients with chronic myeloid leukemia
Published: 2022-06-24 (Crawled : 12:00) - globenewswire.com
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: 6.71%
H: 0.0%
C: -0.1%
NVS | $94.41 0.95% 0.0% 1.4M
|
Health Technology
|
| O: 2.38%
H: 0.0%
C: 0.0%
scemblix treatment chmp novartis leukemia positive
Novartis receives positive CHMP opinion for Tabrecta® for patients with METex14 advanced non-small cell lung cancer
Published: 2022-04-22 (Crawled : 14:00) - globenewswire.com
NVS | $94.41 0.95% 0.0% 1.4M
|
Health Technology
|
| O: -0.6%
H: 0.0%
C: 0.0%
tabrecta chmp novartis positive cancer
Pharming Announces Positive Data from Phase II/III Leniolisib Trial Presented at Clinical Immunology Society 2022 Annual Meeting
Published: 2022-04-01 (Crawled : 16:00) - biospace.com/
NVS | $94.41 0.95% 0.0% 1.4M
|
Health Technology
|
| O: -0.64%
H: 0.6%
C: 0.57%
immunology trial positive
Incyte Announces Positive CHMP Opinion for Ruxolitinib (Jakavi®) for the Treatment of Acute and Chronic Graft-Versus-Host Disease
Published: 2022-03-25 (Crawled : 14:00) - biospace.com/
NVS | $94.41 0.95% 0.0% 1.4M
|
Health Technology
|
| O: 1.14%
H: 0.0%
C: 0.0%
INCY | $53.42 -0.8% -0.8% 1.6M
|
Health Technology
|
| O: 0.33%
H: 0.29%
C: 0.01%
jakavi treatment disease positive chmp
Novartis receives positive CHMP opinion for Kymriah® CAR-T cell therapy for adult patients with relapsed or refractory follicular lymphoma in Europe
Published: 2022-03-25 (Crawled : 12:20) - globenewswire.com
NVS | $94.41 0.95% 0.0% 1.4M
|
Health Technology
|
| O: 1.14%
H: 0.0%
C: 0.0%
kymriah novartis europe car-t positive therapy chmp t-cell
Novartis receives positive CHMP opinion for Jakavi® to treat acute and chronic graft-versus-host disease
Published: 2022-03-25 (Crawled : 12:20) - globenewswire.com
NVS | $94.41 0.95% 0.0% 1.4M
|
Health Technology
|
| O: 1.14%
H: 0.0%
C: 0.0%
jakavi novartis disease positive chmp
Sandoz completes acquisition of GSK’s cephalosporin business, reinforcing leading global position in antibiotics
Published: 2021-10-11 (Crawled : 08:00) - globenewswire.com
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: -0.72%
H: 0.0%
C: 0.0%
NVS | $94.41 0.95% 0.0% 1.4M
|
Health Technology
|
| O: 0.16%
H: 0.19%
C: -0.64%
acquisition antibiotics iot positive
Novartis reports positive health-related quality of life data for 177Lu-PSMA-617 radioligand therapy in patients with advanced prostate cancer at ESMO 2021
Published: 2021-09-16 (Crawled : 23:00) - globenewswire.com
NVS | $94.41 0.95% 0.0% 1.4M
|
Health Technology
|
| O: -0.63%
H: 0.0%
C: 0.0%
prostate cancer positive therapy cancer
Molecular Partners Reports Continued Progress of Ensovibep Global Clinical Program; Positive in vitro Data Demonstrating Maintained Inhibition of Delta and All Other Known Variants of Concern of SARS-CoV-2
Published: 2021-07-08 (Crawled : 06:00) - globenewswire.com
NVS | $94.41 0.95% 0.0% 1.4M
|
Health Technology
|
| O: 0.12%
H: 0.41%
C: 0.33%
positive molecular ensovibep sars-cov-2 in vitro
Novartis presents positive Phase III results from JUNIPERA study supporting Cosentyx® as a potential treatment in a JIA population at EULAR 2021
Published: 2021-06-02 (Crawled : 06:00) - globenewswire.com
NVS | $94.41 0.95% 0.0% 1.4M
|
Health Technology
|
| O: 0.85%
H: 0.37%
C: 0.02%
treatment potential positive results
Novartis announces positive result of phase III study with radioligand therapy 177Lu-PSMA-617 in patients with advanced prostate cancer
Published: 2021-03-23 (Crawled : 07:00) - globenewswire.com
NVS | $94.41 0.95% 0.0% 1.4M
|
Health Technology
|
| O: -0.35%
H: 0.95%
C: 0.06%
prostate cancer positive therapy cancer
Gainers vs Losers
| 49% | 51% |
Top 10 Gainers
KAVL | $6.275 135.02% 57.45% 44M
|
Wholesale Trade
PXMD | $0.7375 79.09% 44.16% 4.5M
|
Health Technology
DYNT | $0.371 -5.12% 43.09% 3.3M
|
Health Technology
LGVN P 3 d | $2.94 73.96% 42.52% 57M
|
HUBC | $1.94 49.23% 32.99% 73M
|
n/a
SPCB | $0.4044 46.52% 31.75% 130M
|
Electronic Technology
ONVO | $1.34 32.66% 24.62% 54M
|
Health Technology
OMQS | $0.6869 32.1% 24.3% 3.6M
|
Professional, Scientific, and T...
SNPO | $10.555 29.67% 22.88% 4M
|
AMBI | $3.72 -26.77% 21.77% 9.8K
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.